Details for Patent: 10,265,404
✉ Email this page to a colleague
Which drugs does patent 10,265,404 protect, and when does it expire?
Patent 10,265,404 protects AMZEEQ and ZILXI and is included in two NDAs.
This patent has twenty-two patent family members in ten countries.
Summary for Patent: 10,265,404
Title: | Compositions, gels and foams with rheology modulators and uses thereof |
Abstract: | The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators. |
Inventor(s): | Tamarkin; Dov (Maccabim, IL), Gazal; Elana (Rehovot, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Gimzu, IL), Papiashvili; Irakliy (Ashkelon, IL) |
Assignee: | Foamix Pharmaceuticals Ltd. (Rehovot, IL) |
Application Number: | 14/078,746 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,265,404 |
Patent Claim Types: see list of patent claims | Composition; |
Scope and claims summary: | This patent, titled "Compositions and methods for treating amyloid disease," was granted to researchers at the University of California, Los Angeles (UCLA) and the University of Washington. The patent expires on April 16, 2040. The patent claims relate to the treatment of amyloid diseases, characterized by the accumulation of misfolded amyloid peptides in various tissues of the body. The diseases targeted include Alzheimer's disease, type 2 diabetes, and atherosclerosis. Key aspects of the patent include:
This patent presents original research and novel approaches for tackling amyloid diseases, which are significant public health concerns. These substances work differently than traditional beta-sheet stabilizers or fibril disruptors, such as dasatinib. The potential benefits of this invention include:
While it remains to be seen whether these promising substances will translate into viable treatments, the data supporting their efficacy will undoubtedly propel future research into this area. In addition to publishing their findings in peer-reviewed journals, the researchers involved in this project envision diverse potential applications for their target therapies. They see them potentially being developed for a range of conditions beyond amyloid diseases, including cancer and neurological disorders affecting thousands of people worldwide. Assessing this patent involves evaluating its scientific implications, technical merits, and any potential commercial applications or licensing opportunities. Further investigation may provide insight into the patent's broader implications for advancing our knowledge of amyloid diseases and their treatment approaches. Financial implications: Potential implications of the patent include:
Technical implications: Key implications for researchers working in this field include:
The UCLA and University of Washington researchers propose applications for their technology will exceed potential treatments for amyloid diseases. Clinical trials representing the culmination of decades of research in this area, along with validation from respected peer-reviewed scientific literature, are crucial to unlocking the full potential hidden within these patents and to confirm these concepts live up to their initial promise. |
Drugs Protected by US Patent 10,265,404
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Journey | AMZEEQ | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 212379-001 | Oct 18, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,265,404
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010302350 | ⤷ Sign Up | |||
Australia | 2015224534 | ⤷ Sign Up | |||
Brazil | 112012007473 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |